Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
In recent transactions filed with the Securities and Exchange Commission, Mary K. Moreland, Executive Vice President at Abbott Laboratories (NYSE:ABT), sold a portion of her common shares. The sale comes as Abbott, a $243 billion healthcare equipment giant, trades near its 52-week high of $141.23. On March 3, 2025, Moreland disposed of 791 shares at an average price of $138.17 per share, totaling approximately $109,292. According to InvestingPro analysis, the stock’s technical indicators suggest it’s currently in overbought territory. This sale leaves her with direct ownership of 95,583 shares.
Earlier, on February 28, 2025, Moreland had disposed of 5,598 shares at $135.87 each, as part of a separate transaction. Following these transactions, Moreland retains an indirect holding of 11,623 shares in the Abbott Laboratories Stock Retirement Trust as of the report date.
In other recent news, Abbott Laboratories has been the focus of several analyst upgrades, reflecting its strong financial outlook and performance in the medical devices sector. Barclays (LON:BARC) raised its price target for Abbott to $158, citing improved earnings projections and gross margin expectations despite challenges from foreign exchange rates and tax increases. Similarly, UBS adjusted its target to $148, highlighting Abbott’s robust organic sales growth and margin expansion in its MedTech products. Bernstein also increased its price target to $138, driven by Abbott’s impressive 14% organic growth in its Medical (TASE:BLWV) Devices segment, with significant contributions from Continuous Glucose Monitoring and Structural Heart products.
Additionally, Abbott has partnered with Cadrenal Therapeutics to conduct a pivotal clinical trial for tecarfarin, a drug aimed at improving treatment for patients with left ventricular assist devices. This collaboration is expected to leverage Abbott’s expertise from HeartMate 3™ LVAD trials to enhance trial design and patient enrollment. The trial is part of Cadrenal’s strategy to address unmet needs in cardiovascular care, and Abbott’s involvement could significantly impact the development of tecarfarin.
These recent developments underscore Abbott’s strong position in the healthcare market, bolstered by strategic collaborations and positive analyst sentiment. The company’s continued focus on innovation and growth in the MedTech sector is reflected in the upward revisions of its stock price targets by multiple analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.